Table 4. Oxytocin (pg/mL) and cortisol (nM or nmol/L) serum concentrations * B = Baseline; Start of test battery = 45′post-oxytocin administration, 90′post-MDMA administration, 150′post-pindolol administration; End of test battery = 120′post-oxytocin administration (first dose), 165′post-MDMA administration, 225′ post-pindolol administration; Statistically significant treatment-placebo contrasts are flagged with an ‘a’, MDMA vs pindolol + MDMA contrasts with a ‘b’.
| Measurement* | ||||||
| Oxytocin | B | Start of test battery | End of test battery | |||
| Conditions | M(SD) | N | M(SD) | N | M(SD) | N |
| MDMA | 6.47 (6.05) | 17 | 12.07 (15.85) | 18 | 7.47 (4.79) | 16 |
| Pindolol + MDMA | 5.67 (3.88) | 17 | 10.71 (11.39) | 18 | 9.96 (6.22) | 11 |
| Oxytocin | 5.42 (4.63) | 14 | 12.85 (11.49)a | 16 | 16.07 (12.62)a | 12 |
| Placebo | 6.24 (5.64) | 16 | 5.24 (6.25) | 15 | 5.05 (4.58) | 14 |
| Cortisol | B | Start of test battery | End of test battery | |||
| MDMA | 704.90 (256.66) | 18 | 735.10 (208.66)a | 18 | 780.13 (361.10)a,b | 17 |
| Pindolol+MDMA | 746.29 (311.36) | 18 | 739.39 (246.35)a | 18 | 799.05 (317.83)a,b | 16 |
| Oxytocin | 653.20 (210.71) | 17 | 351.92 (160.62) | 18 | 323.04 (116.76) | 11 |
| Placebo | 633.42 (178.76) | 17 | 410.53 (154.66) | 15 | 293.43 (129.77) | 14 |